- Home
- ODD vs PHVS Comparison
ODD vs PHVS Comparison
Compare ODD & PHVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ODD | PHVS |
|---|---|---|
| Founded | 2018 | 2015 |
| Country | Israel | Switzerland |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.6B | 1.8B |
| IPO Year | 2022 | 2020 |
Fundamental Metrics
Financial Performance| Metric | ODD | PHVS |
|---|---|---|
| Price | $13.88 | $27.79 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 11 | 9 |
| Target Price | ★ $54.20 | $39.44 |
| AVG Volume (30 Days) | ★ 2.0M | 97.8K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $21.51 | N/A |
| Revenue Next Year | $20.02 | N/A |
| P/E Ratio | $16.73 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $13.09 | $11.51 |
| 52 Week High | $79.18 | $29.80 |
Technical Indicators
Market Signals| Indicator | ODD | PHVS |
|---|---|---|
| Relative Strength Index (RSI) | 17.93 | 56.62 |
| Support Level | N/A | $24.05 |
| Resistance Level | $45.73 | $28.88 |
| Average True Range (ATR) | 1.82 | 1.41 |
| MACD | -1.21 | 0.06 |
| Stochastic Oscillator | 4.27 | 72.22 |
Price Performance
Historical ComparisonAbout ODD ODDITY Tech Ltd.
ODDITY Tech Ltd offers a consumer tech platform that is built to transform the beauty and wellness market. The ODDITY platform is designed to support a portfolio of brands and services that innovate and disrupt the expansive beauty and wellness market. It consumes user data to develop physical beauty and wellness products that deliver performance and functionality. Its brands include SpoiledChild and IL Makiage.
About PHVS Pharvaris N.V.
Pharvaris NV is a late-stage biopharmaceutical company which is engaged in developing novel, oral bradykinin B2 receptor antagonists to prevent and treat HAE attacks. By directly pursuing this clinically therapeutic target with novel small molecules, With positive data in both Phase 2 prophylaxis and studies in HAE, Pharvaris is developing deucrictibant. Pharvaris is currently enrolling a pivotal Phase 3 study for the treatment of HAE attacks and plans to initiate a pivotal Phase 3 study of deucrictibant for the prevention of HAE attacks.